Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined efficacy thresholds” in a phase 2 study. The Swiss pharma had been ...

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint. The study (NCT03827798) had ...

SAN DIEGO — Obinutuzumab and ianalumab are two promising B-cell depleting therapies on the horizon for lupus, according to data presented at the 2024 Congress of Clinical Rheumatology West.“I ...

Agmon-Levin reported that the effect on this outcome was sustained to the end of the open-label period, at 1 year, in 15 (45.5%) of 33 participants who had continued treatment with ianalumab and ...

Meeting Coverage > ASH: Hematology Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP — Drug may potentially "transform" approach to upfront treatment, investigator says by Mike ...